{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:17:07Z","timestamp":1790803027931,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04013-x","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:58:46Z","timestamp":1773298726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of adalimumab in chronic non-infectious anterior uveitis: a retrospective study"],"prefix":"10.1007","volume":"46","author":[{"given":"Guopeng","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"3","key":"4013_CR1","first-page":"164","volume":"52","author":"Eye Immunology Group, Ophthalmology Branch of the Chinese Medical Association","year":"2016","unstructured":"Eye Immunology Group, Ophthalmology Branch of the Chinese Medical Association (2016) Expert consensus on the clinical diagnosis and treatment of acute anterior uveitis in China. Chin J Ophthalmol 52(3):164\u2013166","journal-title":"Chin J Ophthalmol"},{"issue":"7","key":"4013_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3760\/cma.j.cn116022-20250327-00075","volume":"47","author":"GP Ding","year":"2025","unstructured":"Ding GP, Xie GJ, Ju X et al (2025) Clinical observation on the efficacy of adalimumab in the treatment of non-infectious uveitis. Chin J Ocul Traum Occupat Eye Dis 47(7):522\u2013530. https:\/\/doi.org\/10.3760\/cma.j.cn116022-20250327-00075","journal-title":"Chin J Ocul Traum Occupat Eye Dis"},{"issue":"10","key":"4013_CR3","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375(10):932\u2013943. https:\/\/doi.org\/10.1056\/NEJMoa1509852","journal-title":"N Engl J Med"},{"issue":"10050","key":"4013_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183\u20131192. https:\/\/doi.org\/10.1016\/S0140-6736(16)31339-3","journal-title":"Lancet"},{"issue":"7","key":"4013_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","volume":"125","author":"EB Suhler","year":"2018","unstructured":"Suhler EB, Ad\u00e1n A, Br\u00e9zin AP et al (2018) Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology 125(7):1075\u20131087. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.039","journal-title":"Ophthalmology"},{"issue":"10","key":"4013_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.17219\/acem\/125431","volume":"29","author":"A Burek-Michalska","year":"2020","unstructured":"Burek-Michalska A, Turno-Kr\u0119cicka A (2020) Adalimumab in the treatment of non-infectious uveitis. Adv Clin Exp Med 29(10):1231\u20131236. https:\/\/doi.org\/10.17219\/acem\/125431","journal-title":"Adv Clin Exp Med"},{"issue":"3","key":"4013_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ophtha.2019.08.031","volume":"127","author":"A Al-Janabi","year":"2020","unstructured":"Al-Janabi A, El Nokrashy A, Sharief L et al (2020) Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 127(3):410\u2013416. https:\/\/doi.org\/10.1016\/j.ophtha.2019.08.031","journal-title":"Ophthalmology"},{"issue":"1","key":"4013_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/09273948.2018.1491605","volume":"27","author":"H Goto","year":"2019","unstructured":"Goto H, Zako M, Namba K et al (2019) Adalimumab in active and inactive non-infectious uveitis: global results from the VISUAL I and VISUAL II trials. Ocul Immunol Inflamm 27(1):40\u201350. https:\/\/doi.org\/10.1080\/09273948.2018.1491605","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"4013_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","volume":"129","author":"M Leclercq","year":"2022","unstructured":"Leclercq M, Andrillon A, Maalouf G et al (2022) Anti-tumor necrosis factor \u03b1 versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French uveitis network. Ophthalmology 129(5):520\u2013529. https:\/\/doi.org\/10.1016\/j.ophtha.2021.11.013","journal-title":"Ophthalmology"},{"issue":"10","key":"4013_CR10","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s10067-018-4249-1","volume":"37","author":"MJ Kim","year":"2018","unstructured":"Kim MJ, Lee EE, Lee EY et al (2018) Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis. Clin Rheumatol 37(10):2763\u20132770. https:\/\/doi.org\/10.1007\/s10067-018-4249-1","journal-title":"Clin Rheumatol"},{"issue":"5","key":"4013_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Rodevand E, Holck P et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696\u2013701. https:\/\/doi.org\/10.1136\/ard.2008.092585","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4013_CR12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210563","volume":"76","author":"E Lie","year":"2017","unstructured":"Lie E, Lindstr\u00f6m U, Zverkova-Sandstr\u00f6m T et al (2017) Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis 76(9):1515\u20131521. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210563","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4013_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3760\/cma.j.cn112138-20211226-00913","volume":"61","author":"F Huang","year":"2022","unstructured":"Huang F, Zhu J, Wang YH et al (2022) Recommendations for diagnosis and treatment of ankylosing spondylitis. Chin J Intern Med 61(8):893\u2013900. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20211226-00913","journal-title":"Chin J Intern Med"},{"key":"4013_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2019.06.007","volume":"207","author":"S Horton","year":"2019","unstructured":"Horton S, Jones AP, Guly CM et al (2019) Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE trial. Am J Ophthalmol 207:170\u2013174. https:\/\/doi.org\/10.1016\/j.ajo.2019.06.007","journal-title":"Am J Ophthalmol"},{"key":"4013_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.108322","volume":"211","author":"ES Sen","year":"2020","unstructured":"Sen ES, Ramanan AV (2020) Juvenile idiopathic arthritis-associated uveitis. Clin Immunol 211:108322. https:\/\/doi.org\/10.1016\/j.clim.2019.108322","journal-title":"Clin Immunol"},{"key":"4013_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013818.pub2","volume":"10","author":"WD Renton","year":"2022","unstructured":"Renton WD, Jung J, Palestine AG (2022) Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database Syst Rev 10:CD013818. https:\/\/doi.org\/10.1002\/14651858.CD013818.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4013_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020629","volume":"11","author":"J Corredores","year":"2023","unstructured":"Corredores J, Vofo B, Amer R (2023) Uveitis in children: the role of biological agents in its management. Biomedicines 11(2):629. https:\/\/doi.org\/10.3390\/biomedicines11020629","journal-title":"Biomedicines"},{"issue":"2","key":"4013_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.12290\/xhyxzz.2023-0090","volume":"14","author":"Immunology Group of Pediatrics Branch of Chinese Medical Association, China Alliance for Pediatric Rheumatic and Immunologic Diseases, National Clinical Research Center for Child Health and Diseases, Rheumatology and Immunology Alliance","year":"2023","unstructured":"Immunology Group of Pediatrics Branch of Chinese Medical Association, China Alliance for Pediatric Rheumatic and Immunologic Diseases, National Clinical Research Center for Child Health and Diseases, Rheumatology and Immunology Alliance (2023) Chinese expert consensus on the diagnosis and treatment of juvenile idiopathic arthritis\u2013associated uveitis. Med J Peking Union Med Coll Hosp 14(2):247\u2013256. https:\/\/doi.org\/10.12290\/xhyxzz.2023-0090","journal-title":"Med J Peking Union Med Coll Hosp"},{"issue":"2","key":"4013_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/09273948.2010.542269","volume":"19","author":"D Wakefield","year":"2011","unstructured":"Wakefield D, Chang JH, Amjadi S et al (2011) What is new HLA-B27 acute anterior uveitis? Ocul Immunol Inflamm 19(2):139\u2013144. https:\/\/doi.org\/10.3109\/09273948.2010.542269","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"4013_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09273948.2016.1234625","volume":"25","author":"J Gueudry","year":"2017","unstructured":"Gueudry J, Thorne JE, Bansie R et al (2017) Biologic therapy for HLA-B27-associated ocular disorders. Ocul Immunol Inflamm 25(2):169\u2013178. https:\/\/doi.org\/10.1080\/09273948.2016.1234625","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"4013_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.18502\/jovr.v16i3.9440","volume":"16","author":"N Ebrahimiadib","year":"2021","unstructured":"Ebrahimiadib N, Berijani S, Ghahari M et al (2021) Ankylosing spondylitis. J Ophthalmic Vis Res 16(3):462\u2013469. https:\/\/doi.org\/10.18502\/jovr.v16i3.9440","journal-title":"J Ophthalmic Vis Res"},{"issue":"7","key":"4013_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","volume":"77","author":"P Quartier","year":"2018","unstructured":"Quartier P, Baptiste A, Despert V et al (2018) ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis 77(7):1003\u20131009. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212089","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"4013_CR23","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1614160","volume":"377","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, Dick AD, Benton D et al (2017) Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 377(16):1513\u20131523. https:\/\/doi.org\/10.1056\/NEJMoa1614160","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"4013_CR24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.3109\/09273948.2016.1158279","volume":"25","author":"F Gao","year":"2017","unstructured":"Gao F, Zhao C, Cheng G et al (2017) Clinical patterns of uveitis in a tertiary center in North China. Ocul Immunol Inflamm 25(Suppl 1):S1\u2013S7. https:\/\/doi.org\/10.3109\/09273948.2016.1158279","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"4013_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244\u2013279. https:\/\/doi.org\/10.1016\/j.pharmthera.2007.10.001","journal-title":"Pharmacol Ther"},{"issue":"5","key":"4013_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA et al (2018) Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis. Ophthalmology 125(5):757\u2013773. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.017","journal-title":"Ophthalmology"},{"issue":"6","key":"4013_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","volume":"128","author":"EB Suhler","year":"2021","unstructured":"Suhler EB, Jaffe GJ, Fortin E et al (2021) Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 128(6):899\u2013909. https:\/\/doi.org\/10.1016\/j.ophtha.2020.10.036","journal-title":"Ophthalmology"},{"issue":"4","key":"4013_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB et al (2013) Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis 72(4):517\u2013524. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201244","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"4013_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha\u2013neutralizing agent. N Engl J Med 345(15):1098\u20131104. https:\/\/doi.org\/10.1056\/NEJMoa011110","journal-title":"N Engl J Med"},{"issue":"1","key":"4013_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3760\/cma.j.cn511434-20240104-00005","volume":"40","author":"XZ Wang","year":"2024","unstructured":"Wang XZ, Zheng WJ, Zhang XM (2024) Interpretation of the Chinese expert consensus on treatment of non-infectious uveitis with anti\u2013tumor necrosis factor-\u03b1 monoclonal antibody. Chin J Ocul Fundus Dis 40(1):20\u201326. https:\/\/doi.org\/10.3760\/cma.j.cn511434-20240104-00005","journal-title":"Chin J Ocul Fundus Dis"},{"issue":"6","key":"4013_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.survophthal.2015.05.005","volume":"60","author":"M Cordero-Coma","year":"2015","unstructured":"Cordero-Coma M, Sobrin L (2015) Anti\u2013tumor necrosis factor-\u03b1 therapy in uveitis. Surv Ophthalmol 60(6):575\u2013589. https:\/\/doi.org\/10.1016\/j.survophthal.2015.05.005","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"4013_CR32","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","volume":"125","author":"JL Mart\u00edn-Varillas","year":"2018","unstructured":"Mart\u00edn-Varillas JL, Calvo-R\u00edo V, Beltr\u00e1n E et al (2018) Successful optimization of adalimumab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease. Ophthalmology 125(9):1444\u20131451. https:\/\/doi.org\/10.1016\/j.ophtha.2018.02.020","journal-title":"Ophthalmology"},{"key":"4013_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ajo.2023.09.012","volume":"258","author":"F Pichi","year":"2024","unstructured":"Pichi F, Smith SD, Goldstein DA et al (2024) The Humira in Ocular Inflammations Taper (HOT) study. Am J Ophthalmol 258:87\u201398. https:\/\/doi.org\/10.1016\/j.ajo.2023.09.012","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"4013_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/09273948.2024.2350551","volume":"33","author":"PD Yuan","year":"2025","unstructured":"Yuan PD, Hu YW, Chen XQ et al (2025) Adalimumab dose reduction and withdrawal in stable non-infectious pediatric uveitis: an open-label, prospective, pilot study. Ocul Immunol Inflamm 33(3):332\u2013339. https:\/\/doi.org\/10.1080\/09273948.2024.2350551","journal-title":"Ocul Immunol Inflamm"},{"key":"4013_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(24)02468-1","volume":"405","author":"N Acharya","year":"2025","unstructured":"Acharya N, Crouch B, Coyne C et al (2025) Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial. Lancet 405:303\u2013313. https:\/\/doi.org\/10.1016\/S0140-6736(24)02468-1","journal-title":"Lancet"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04013-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04013-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04013-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:58:51Z","timestamp":1773298731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04013-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4013"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04013-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8297406\/v1","asserted-by":"object"}]},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The requirement for informed consent was waived by the Ethics Committee of Baoji People\u2019s Hospital due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. All data were anonymized to protect patient privacy. Given the retrospective nature of the study and the absence of any patient intervention, the Ethics Committee of Baoji People\u2019s Hospital approved the study and waived the requirement for informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"153"}}